Hikma Pharmaceuticals (HKMPF) Income Statement
Hikma Pharmaceuticals Income Statement
Last quarter (Q2 2026), Hikma Pharmaceuticals's total revenue was $1.71B, an increase of 9.23% from the same quarter last year. In Q2, Hikma Pharmaceuticals's net income was $221.17M. See Hikma Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 3.35B | $ 3.13B | $ 2.88B | $ 2.52B | $ 2.55B | |
| $ 1.44B | $ 1.42B | $ 1.41B | $ 1.26B | $ 1.30B | |
| $ 808.00M | $ 803.00M | $ 1.04B | $ 976.00M | $ 715.00M | |
| Depreciation and Amortization | $ 238.00M | $ 197.56M | $ 198.00M | $ 193.00M | $ 167.78M |
| $ 845.00M | $ 805.56M | $ 817.00M | $ 485.00M | $ 767.78M | |
| $ 579.92M | $ 612.00M | $ 367.00M | $ 591.00M | $ 634.00M | |
| $ -50.03M | $ -157.00M | $ -86.00M | $ -49.00M | $ -38.00M | |
| $ 529.89M | $ 455.00M | $ 281.00M | $ 233.00M | $ 544.00M | |
| $ 410.43M | $ 359.00M | $ 190.00M | $ 188.00M | $ 421.00M | |
| Per Share Metrics | |||||
| Basic EPS | $ 1.86 | $ 1.61 | $ 0.85 | $ 0.84 | $ 1.82 |
| Diluted EPS | $ 1.84 | $ 1.61 | $ 0.85 | $ 0.84 | $ 1.81 |
| Weighted Average Shares Outstanding | 220.59M | 222.98M | 222.37M | 223.73M | 231.00M |
| Weighted Average Shares Outstanding (Diluted) | 222.68M | 223.49M | 222.37M | 225.00M | 233.00M |
Currency in USD
